Stock Scorecard
Stock Summary for Ardelyx Inc (ARDX) - $6.43 as of 4/24/2024 8:15:00 PM EST
Total Score
11 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ARDX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ARDX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ARDX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ARDX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for ARDX
Financial Details for ARDX
Company Overview |
|
---|---|
Ticker | ARDX |
Company Name | Ardelyx Inc |
Country | USA |
Description | Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 6.43 |
Last Day Price Updated | 4/24/2024 8:15:00 PM EST |
Last Day Volume | 5,448,698 |
Average Daily Volume | 5,415,069 |
52-Week High | 10.13 |
52-Week Low | 3.16 |
Last Price to 52 Week Low | 103.48% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 100.27 |
Sector PE | 60.54 |
5-Year Average PE | -6.70 |
Free Cash Flow Ratio | 8.14 |
Industry Free Cash Flow Ratio | 12.60 |
Sector Free Cash Flow Ratio | 30.19 |
Current Ratio Most Recent Quarter | 4.88 |
Total Cash Per Share | 0.79 |
Book Value Per Share Most Recent Quarter | 0.72 |
Price to Book Ratio | 9.85 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 13.20 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 232,686,000 |
Market Capitalization | 1,496,170,980 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 1.70% |
Reported EPS 12 Trailing Months | -0.30 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -0.30 |
Net Income Twelve Trailing Months | -66,067,000 |
Net Income Past Year | -66,067,000 |
Net Income Prior Year | -67,207,000 |
Quarterly Revenue Growth YOY | -22.20% |
5-Year Revenue Growth | 115.19% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 184,299,000 |
Total Cash Past Year | 184,299,000 |
Total Cash Prior Year | 123,909,000 |
Net Cash Position Most Recent Quarter | 134,477,000 |
Net Cash Position Past Year | 134,477,000 |
Long Term Debt Past Year | 49,822,000 |
Long Term Debt Prior Year | 26,711,000 |
Total Debt Most Recent Quarter | 49,822,000 |
Equity to Debt Ratio Past Year | 0.77 |
Equity to Debt Ratio Most Recent Quarter | 0.77 |
Total Stockholder Equity Past Year | 166,816,000 |
Total Stockholder Equity Prior Year | 98,329,000 |
Total Stockholder Equity Most Recent Quarter | 166,816,000 |
Options |
|
Put/Call Ratio | 0.40 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.43 |
MACD Signal | -0.39 |
20-Day Bollinger Lower Band | 5.39 |
20-Day Bollinger Middle Band | 7.80 |
20-Day Bollinger Upper Band | 10.21 |
Beta | 0.82 |
RSI | 36.16 |
50-Day SMA | 5.44 |
200-Day SMA | 4.01 |
System |
|
Modified | 4/24/2024 5:51:56 PM EST |